Showing posts with label potential. Show all posts
Showing posts with label potential. Show all posts

Saturday, September 3, 2011

Specialized regulatory T cell stifles antibody production centers: Discovery has potential implications for cancer, autoimmune disease

ScienceDaily (July 25, 2011) — A regulatory T cell that expresses three specific genes shuts down the mass production of antibodies launched by the immune system to attack invaders, a team led by scientists at The University of Texas MD Anderson Cancer Center reported online in the journal Nature Medicine.See Also:Health & MedicineLymphomaImmune SystemStem CellsBrain TumorCancerLung CancerReferenceNatural killer cellT cellLymph nodeHeat shock protein

"Regulatory T cells prevent unwanted or exaggerated immune system responses, but the mechanism by which they accomplish this has been unclear," said paper senior author Chen Dong, Ph.D., professor in MD Anderson's Department of Immunology and director of the Center for Inflammation and Cancer.

"We've identified a molecular pathway that creates a specialized regulatory T cell, which suppresses the reaction of structures called germinal centers. This is where immune system T cells and B cells interact to swiftly produce large quantities of antibodies," Dong said.

The discovery of the germinal center off-switch, which comes two years after Dong and colleagues identified the mechanisms underlying a helper T cell that activates the centers, has potential implications for cancer and autoimmune diseases.

"In some types of cancer, the presence of many regulatory T cells is associated with poor prognosis," Dong said. "The theory is those cells suppress an immune system response in the tumor's microenvironment that otherwise might have attacked the cancer."

However, in B cell lymphomas, overproliferation and mutation of B cells are the problems, Dong said. Hitting the regulatory T cell off-switch might help against lymphomas and autoimmune diseases, while blocking it could permit an immune response against other cancers.

Antibody production central

Germinal centers are found in the lymph nodes and the spleen. They serve as gathering points for B and T cell lymphocytes, infection-fighting white blood cells.

When the adaptive immune system detects an invading bacterium or virus, B cells present a piece of the invader, an antigen, to T cells. The antigen converts a naïve T cell to a helper T cell that secretes cytokines, which help the B cells expand and differentiate into specialized antibodies to destroy the intruder.

"Germinal centers have mostly B cells with a few helper T cells to regulate them. The B cells mutate to make high-affinity antibodies and memory B cells for long-term immunity. The cell population in the germinal center structures replicates in an average of several hours, one of the fastest rates of cell replication known in mammals," Dong said.

Tracking down specialized T cell

In the Nature Medicine paper, Dong and colleagues found that a subgroup of regulatory T cells that expresses two genes, Bcl-6 and CXCR5, moves into germinal centers in both mice and humans, where they have access to B cells.

(Bcl-6 produces a protein called a transcription factor, which moves into the cell nucleus to regulate other genes. CXCR5 is a receptor protein for a signaling molecule called CXCL13.)

They also found that the Bcl-6/CXCR5 T cells aren't produced in the thymus, with other T cells, but are generated by regulatory T cell precursor cells that express Foxp3, another transcription factor.

Knocking out the regulatory T cells that express all three proteins in mice resulted in increased germinal center production of antibodies. They named this key T cell the T follicular regulatory cell, or Tfr.

In a 2009 paper in the journal Science, the researchers found that naïve T cells that expressed Bcl-6 and CXCR5 also gathered in the B cell zone of germinal centers. Expression of Bcl6 converted the T cell into a T follicular helper (Tfh) cell that launches antibody production in the germinal centers.

With Tfr turning germinal centers off and Tfh turning them on, we could potentially regulate antibody production, Dong noted. Increasing Tfr production could be a new approach to treating autoimmune inflammatory disorders, such as lupus and rheumatoid arthritis.

The team's research was funded by grants from the National Institutes of Health, the Leukemia and Lymphoma Society, MD Anderson, the American Heart Association, Doris Duke Charitable Foundation Clinical Scientist Development Award and the China Ministry of Science and Technology Protein Science Key Research Project.

Co-authors with Dong are first author Yeonseok Chung, Ph.D., Shinya Tanaka, Ph.D., Roza Nurieva, Ph.D., Gustavo Martinez, Yi-Hong Wang and Joseph Reynolds, Ph.D., of MD Anderson's Department of Immunology and the Center for Cancer Immunology; Chung also is with The University of Texas Health Science Center at Houston Institute of Molecular Medicine; Seema Rawal and Sattva Neelapu, M.D., of MD Anderson's Department of Lymphoma and Myeloma, also of the Center for Cancer Immunology; and Ziao-hui Zhou, M.D., Hui-min Fan, M.D., and Zhong-ming Liu, M.D., of Shanghai Dong Fang Hospital, Shanghai, China.

Email or share this story:

Thursday, August 18, 2011

Scientists discover potential stroke treatment that may extend time to prevent brain damage

ScienceDaily (July 25, 2011) — A naturally occurring substance shrank the size of stroke-induced lesions in the brains of experimental mice -- even when administered as much as 12 hours after the event, Stanford University School of Medicine researchers have shown. The substance, alpha-B-crystallin, acts as a brake on the immune system, lowering levels of inflammatory molecules whose actions are responsible for substantial brain damage above and beyond that caused by the initial oxygen deprivation of a stroke.See Also:Health & MedicineStroke PreventionHeart DiseaseElder CareMind & BrainBrain InjuryStrokeCaregivingReferenceMulti-infarct dementiaBrain damageStrokeNeurology

The finding, which will be published online July 25 in Proceedings of the National Academy of Sciences, is of great potential significance. Every year brings nearly 800,000 new stroke patients in North America. "That's one every 40 seconds," said Gary Steinberg, MD, PhD, director of Stanford's Institute for Neuro-Innovation and Translational Neurosciences and one of the study's two senior authors. Steinberg is also the Bernard and Ronni Lacroute-William Randolph Hearst Professor of Neurosurgery and the Neurosciences, and chair of neurosurgery at the medical school.

The largest single cause of severe neurological disability and the third-leading cause of death in the United States, stroke accounts for an estimated $74 billion annually in related costs, including treatment and additional assistance for the three of every four stroke patients whose ability to perform the activities of daily life is impaired. Strokes are caused by a sudden drop in the flow of blood to the brain resulting from a clot or, less often, bleeding. One of every three stroke patients is under the age of 65. In all, there are 5.4 million stroke survivors in the United States and 15 million worldwide.

The only currently approved drug for stroke -- tissue plasminogen activator, or tPA -- dissolves clots that keep oxygenated blood from reaching brain tissue. To be effective, tPA must be administered within about 4.5 hours after the stroke. But patients' brains must first be scanned to rule out the possibility that the stroke was caused by bleeding, which tPA would exacerbate, rather than by blockage.

Moreover, tPA does nothing to counter the stroke's insidious inflammatory aftershock: a flood of noxious chemicals secreted by angry immune cells that rush in to the affected area, causing significant further damage.

Alpha-B-crystallin appears to act as a sponge, sopping up those bad actors and stopping inflammation from making a bad situation worse.

Alpha-B-crystallin is a major structural protein in the eye's lens. It is also constantly made in the heart. In other tissues, including the brain, its production can be triggered by stressful events, such as oxygen deprivation or excessive heat or cold. Growing evidence suggests that alpha-B-crystallin can help curb inflammatory activity in the brain.

"The brain doesn't roll over and play dead when it's under attack," said Lawrence Steinman, MD, the other senior author of the new study, who is the George A. Zimmermann Professor of Neurology and Neurological Sciences and Pediatrics as well as chair of Stanford's interdepartmental program in immunology.

In an earlier study, published in Nature in 2007, Steinman and his colleagues found that the presence of alpha-B-crystallin could help reduce the severity of brain damage caused by multiple sclerosis, a chronic, debilitating autoimmune disease of the brain. Other studies published this year by his group have shown that alpha-B-crystallin limits the damage caused by blood-supply cutoffs to heart tissue and the retina.

It seemed logical to see if this protein could mitigate the effects of a stroke. "We made a jump from its relevance in inflammatory diseases such as multiple sclerosis," Steinberg said. "To my knowledge, nobody had looked at concentrations of alpha-B-crystallin after a stroke, either in people or in an experimental animal model before."

So, along with first authors Ahmet Arac, MD, a postdoctoral scholar in Steinberg's lab, and Steinman's former graduate student Sarah Brownell, PhD, Steinberg and Steinman turned to a standard animal model: the laboratory mouse. They found that, in mice bioengineered to lack alpha-B-crystallin, experimentally induced stroke lesions were more massive than those induced in otherwise genetically similar mice whose cells were capable of making the protein. The alpha-B-crystallin-deficient mice had worse neurological function after the stroke than did the normal mice.

The researchers also found that supplying synthetic alpha-B-crystallin to the deficient mice reduced brain-lesion sizes after a stroke, even when the substance was administered 12 hours after the stroke was induced. And they saw elevated alpha-B-crystallin levels in blood plasma from both human patients and mice after a stroke. (The human samples were obtained from study co-author Gregory Albers, MD, the Coy Foundation Professor of Neurology and Neurological Sciences and the director of the Stanford Stroke Center).

"In younger patients, the larger the stroke, the higher the concentration of alpha-B-crystallin," said Steinberg. Interestingly, increased alpha-B-crystallin levels were not detected in plasma from patients over the age of 80, whose strokes typically have worse consequences than those affecting younger patients.

Finally, the investigators demonstrated that alpha-B-crystallin-treated mice produce fewer inflammatory immune-signaling molecules and more anti-inflammatory ones than untreated mice.

At the doses given to the mice in this study, alpha-B-crystallin appeared to be nontoxic. "This is a naturally occurring molecule the body is already producing, although maybe just not enough of it," said Steinberg. "We're just supplementing it." If further studies by other labs and in other models confirm and extend the findings, alpha-B-crystallin may be an excellent candidate for clinical trials in stroke, Steinman and Steinberg both said.

"This is the first demonstration of an efficacious brain-protecting agent that targets the inflammatory aspect of stroke in a novel way, and it can be given at quite a delay," said Thomas Carmichael, MD, PhD, professor and vice chair of neurology at the David Geffen School of Medicine at UCLA. Carmichael, a stroke expert, did not participate in the study but is familiar with its methodology and results. "Tissue plasminogen activator has a fairly narrow risk-to-benefit ratio. The longer you wait, the more likely it is to stimulate a hemorrhage."

Email or share this story:

Thursday, August 4, 2011

Shining a light on the elusive 'blackbody' of energy research: Designer material has potential applications for thermophotovoltaics

ScienceDaily (July 23, 2011) — A designer metamaterial has shown it can engineer emitted "blackbody" radiation with an efficiency beyond the natural limits imposed by the material's temperature, a team of researchers led by Boston College physicist Willie Padilla report in the current edition of Physical Review Letters.See Also:Matter & EnergyMaterials ScienceThermodynamicsPhysicsPetroleumEnergy TechnologyEngineeringReferenceBlack bodyRadiant energyElectromagnetic spectrumHeat

A "blackbody" object represents a theorized ideal of performance for a material that perfectly absorbs all radiation to strike it and also emits energy based on the material's temperature. According to this blackbody law, the energy absorbed is equal to the energy emitted in equilibrium.

The breakthrough reported by Padilla and colleagues from Duke University and SensorMetrix, Inc., could lead to innovative technologies used to cull energy from waste heat produced by numerous industrial processes. Furthermore, the human-made metamaterial offers the ability to control emissivity, which could further enhance energy conversion efficiency.

"For the first time, metamaterials are shown to be able to engineer blackbody radiation and that opens the door for a number of energy harvesting applications," said Padilla. "The energy a natural surface emits is based on its temperature and nothing more. You don't have a lot of choice. Metamaterials, on the other hand, allow you to tailor that radiation coming off in any desirable manner, so you have great control over the emitted energy."

Researchers have long sought to find the ideal "blackbody" material for use in solar or thermoelectric energy generation. So far, the hunt for such a class of thermal emitters has proved elusive. Certain rare earth oxides are in limited supply and expensive, in addition to being almost impossible to control. Photonic crystals proved to be inferior emitters that failed to yield significant efficiencies.

Constructed from artificial composites, metamaterials are designed to give them new properties that exceed the performance limits of their actual physical components and allow them to produce "tailored" responses to radiation. Metamaterials have exhibited effects such as a negative index of refraction and researchers have combined metamaterials with artificial optical devices to demonstrate the "invisibility cloak" effect, essentially directing light around a space and masking its existence.

Three years ago, the team developed a "perfect" metamaterial absorber capable of absorbing all of the light that strikes it thanks to its nano-scale geometric surface features. Knowing that, the researches sought to exploit Kirchoffs's law of thermal radiation, which holds that the ability of a material to emit radiation equals its ability to absorb radiation.

Working in the mid-infrared range, the thermal emitter achieved experimental emissivity of 98 percent. A dual-band emitter delivered emission peaks of 85 percent and 89 percent. The results confirmed achieving performance consistent with Kirchoff's law, the researchers report.

"We also show by performing both emissivity and absorptivity measurements that emissivity and absorptivity agree very well," said Padilla. "Even though the agreement is predicted by Kirchoff's law, this is the first time that Kirchoff's law has been demonstrated for metamaterials."

The researchers said altering the composition of the metamaterial can results in single-, dual-band and broadband metamaterials, which could allow greater control of emitted photons in order to improve energy conversion efficiency.

"Potential applications could lie in energy harvesting area such as using this metamaterial as the selective thermal emitter for thermophotovoltaic (TPV) cells," said Padilla. "Since this metamaterial has the ability to engineer the thermal radiation so that the emitted photons match the band gap of the semiconductor -- part of the TPV cell -- the converting efficiency could be greatly enhanced.

In addition to Padilla, the research team included BC graduate student Xianliang Liu, Duke University's Nan Marie Jokerst and Talmage Tyler and SensorMetrix, Inc., researchers Tatiana Starr and Anthony F. Starr.

Email or share this story: